Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684957 · ClinicalTrials.gov registry record · Phase 1
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00684957 is a Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 5 participants.
The verdict
NCT00684957, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
Interventions
- DRUG Recombinant Human Growth Hormone
- DRUG Recombinant Human IGF-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684957
The ClinicalTrials.gov registry entry for NCT00684957 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Recombinant Human Growth Hormone is the first listed.
NCT00684957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00684957 about?
NCT00684957 is a clinical study titled "Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors". The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
What is the current status of trial NCT00684957?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2008-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00684957?
The interventions under investigation include: Recombinant Human Growth Hormone (DRUG), Recombinant Human IGF-1 (DRUG).
Who is sponsoring clinical trial NCT00684957?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.